KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.

医学 克拉斯 西妥昔单抗 耐受性 内科学 肿瘤科 临床研究阶段 非小细胞肺癌 表皮生长因子受体抑制剂 表皮生长因子受体 养生 癌症 胃肠病学 结直肠癌 肺癌 不利影响 化疗 A549电池
作者
Vanesa Gregorc,María González‐Cao,Stefania Salvagni,Anna Koumarianou,Ignacio Gil‐Bazo,Michele Maio,Santiago Viteri,Margarita Majem,Vanesa Gutiérrez,Reyes Bernabé,Miguel F. Sanmamed,Huaqiang Zhu,Haige Shen,Sheng Wang,Rafael Rosell
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (17_suppl): LBA8511-LBA8511 被引量:3
标识
DOI:10.1200/jco.2024.42.17_suppl.lba8511
摘要

LBA8511 Background: Fulzerasib (GFH925), a KRAS G12C inhibitor, showed substantial efficacy in previously treated NSCLC patients (pts) as monotherapy. Activation of epidermal growth factor receptor (EGFR) is identified to be one of the dominant mechanisms for KRAS inhibition resistance. Preclinical evidence showed synergistic activity in KRAS G12C mutant NSCLC modeling using fulzerasib in combination with cetuximab. Here we report the first results for a KRAS G12C inhibitor combined with an anti-EGFR antibody in NSCLC pts as front-line treatment. Methods: KROCUS (NCT05756153) was an open-label, single-arm, multi-center, Phase II study with the primary objective to evaluate the efficacy of fulzerasib in combination with cetuximab in pts with previously untreated advanced NSCLC harboring KRAS G12C mutation. Secondary objectives included safety/tolerability, pharmacokinetics and biomarkers. Pts were enrolled to receive fulzerasib (oral, 600 mg BID) and cetuximab (intravenous, 500 mg/m 2 , every two weeks [Q2W]) combination treatment in a 28-day cycle. Results: As of Jan. 30, 2024, a total of 27 pts (median age: 68 yrs old; 55.6% female) were treated, 11 (40.7%) with baseline brain metastases. Of 20 pts who had at least one post-treatment tumor assessment, ORR was 80.0% (95% CI: 56.3, 94.3, including one CR), of whom eight pts had ≥ 50% tumor shrinkages in the target lesions. Disease control rate (DCR) was 100% (95% CI: 83.2, 100.0). Five out of seven pts (71.4%) with brain metastases achieved PRs. Nine pts with baseline PD-L1 expression tested (six TPS≥1% and three TPS <1%) all achieved PRs. The overall safety profile of the combination was favorable. Treatment-related adverse events (TRAEs) of any grade occurred in 21 (77.8%) pts. 5 pts (18.5%) experienced G3 TRAEs and no G4 or 5 TRAEs. Three pts (11.1%) had dose reduction/interruption with fulzerasib due to TRAEs but no pts discontinued treatment while one pt (3.7%) had dose reduction/interruption and three (11.1%) discontinued cetuximab due to TRAEs. Table 1 shows the most common TRAEs or G3 TRAEs. Conclusions: The preliminary data from ongoing KROCUS study has demonstrated very promising efficacy and favorable safety profile of fulzerasib + cetuximab in the first line setting of KRAS G12C mutated NSCLC. More data will be generated to provide clinical evidence supporting this combination as a potential frontline therapy. Clinical trial information: NCT05756153 . [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Maestro_S的应助被黄家宝采纳,获得10
刚刚
冷酷以山完成签到,获得积分10
刚刚
gxiaxia完成签到,获得积分10
1秒前
Owen的应助被心殇采纳,获得30
1秒前
无知完成签到,获得积分10
1秒前
Xc完成签到,获得积分10
1秒前
1秒前
h11的应助被yy采纳,获得10
2秒前
2秒前
111完成签到,获得积分10
2秒前
章海鹏完成签到 ,获得积分10
2秒前
erhya完成签到,获得积分10
2秒前
顾矜的应助被王kk采纳,获得10
2秒前
华仔的应助被Rony采纳,获得10
2秒前
3秒前
hustzwqq完成签到,获得积分10
3秒前
典雅的雪晴完成签到,获得积分10
3秒前
3秒前
完美世界的应助被辉太狼采纳,获得10
3秒前
无敌淀粉肠完成签到,获得积分10
4秒前
虚幻的冷松完成签到,获得积分10
4秒前
冷酷以山发布了新的文献求助10
4秒前
VENTUS完成签到,获得积分10
4秒前
受伤的严青完成签到 ,获得积分10
5秒前
chen完成签到,获得积分10
5秒前
小蘑菇的应助被正直的的白羊采纳,获得10
5秒前
DavidChen完成签到,获得积分10
5秒前
5秒前
可乐完成签到,获得积分10
5秒前
Lychee完成签到,获得积分10
5秒前
Rocc完成签到,获得积分10
6秒前
一叶知秋完成签到,获得积分10
6秒前
星辰大海的应助被哈哈采纳,获得10
6秒前
科隆龙完成签到,获得积分10
6秒前
zzz完成签到,获得积分10
7秒前
阿怪12333完成签到,获得积分10
7秒前
细腻驳发布了新的文献求助10
7秒前
李多意发布了新的文献求助10
7秒前
Elias完成签到,获得积分10
8秒前
任性行天完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159212
求助须知:如何正确求助?哪些是违规求助? 9554678
关于积分的说明 21720538
捐赠科研通 7748887
什么是DOI,文献DOI怎么找? 3427184
关于科研通互助平台的介绍 2552092
邀请新用户注册赠送积分活动 2471464